文献速递免疫规划

一项2/3期试验:研究单价奥密克戎JN.1适配BNT162b2新冠疫苗在18岁及以上成人中的安全性和免疫原性

A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old.
PubMed 文献 · Vaccine · 2025-02-24

53名健康成人(18-55岁27人,>55岁26人)接种单价奥密克戎JN.1适配BNT162b2疫苗,评估7天内局部反应和全身事件、1个月内不良事件及1个月中和抗体滴度。未见新的安全性信号,JN.1适配疫苗诱导的针对奥密克戎JN.1、KP.2和KP.3的中和滴度高于XBB.1.5适配疫苗,两个年龄组GMT总体相似。

要点

  • JN.1适配BNT162b2疫苗7天内局部反应和全身事件多为轻至中度,不良事件不频繁。
  • 接种1个月后,JN.1适配疫苗针对奥密克戎JN.1、KP.2和KP.3的中和滴度高于XBB.1.5适配疫苗。
  • JN.1适配疫苗组18-55岁和>55岁年龄组的GMT总体相似。

核心结论

  • 这些安全性和免疫原性数据支持2024-2025季节使用JN.1谱系适配疫苗。

研究设计与样本

  • 2/3期试验,53名健康成人(18-55岁n=27;>55岁n=26)接种单价奥密克戎JN.1适配BNT162b2疫苗。
  • 主要安全性终点为接种后7天内局部反应和全身事件、1个月内不良事件、6个月内严重不良事件,本文报告1个月内安全性数据。
  • 基线及接种后1个月检测针对奥密克戎JN.1、KP.2、KP.3及XBB.1.5的血清50%中和滴度。
  • 免疫原性与本试验先前子研究中接种单价XBB.1.5适配BNT162b2的组进行比较,按年龄和基线SARS-CoV-2感染状态匹配。

主要发现

  • 未见新的安全性信号;接种后7天内局部反应和全身事件一般为轻至中度严重程度,不良事件不频繁。
  • 接种1个月后,JN.1适配BNT162b2诱导的针对奥密克戎JN.1、KP.2和KP.3的中和滴度高于XBB.1.5适配BNT162b2诱导的滴度。
  • 在JN.1适配BNT162b2组中,18-55岁和>55岁年龄组的GMT总体相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 remains a substantial burden in vulnerable populations, including older adults and immunocompromised individuals. It was recommended that 2024-2025 COVID-19 vaccine formulations should target a monovalent JN.1 lineage. Here we provide preliminary data on the safety, tolerability, and immunogenicity of a monovalent Omicron JN.1-adapted BNT162b2 vaccine. METHODS: Fifty-three healthy adults ≥18 years old (18-55 years, n = 27; >55 years, n = 26) were vaccinated with Omicron JN.1-adapted BNT162b2. Primary safety endpoints were local reactions and systemic events through 7 days, adverse events (AEs) through 1 month, and serious AEs through 6 months; safety data through 1 month are presented here. Serum 50 % neutralizing titers against Omicron JN.1, KP.2, and KP.3, as well as XBB.1.5 were measured at baseline and 1 month after vaccination. Immunogenicity was also compared to a group who received monovalent XBB.1.5-adapted BNT162b2 in a previous substudy of this trial matched by age and baseline SARS-CoV-2 infection status to current substudy participants. RESULTS: There were no new safety signals; local reactions and systemic events through 7 days of vaccination were generally mild to moderate in severity, and AEs were infrequent. One month after vaccination, JN.1-adapted BNT162b2 induced neutralizing titers against Omicron JN.1, KP.2, and KP.3 that were higher than those induced by XBB.1.5-adapted BNT162b2. In the JN.1-adapted BNT162b2 group, GMTs were generally similar for the 18-55- and >55-year-old age groups. CONCLUSION: Collectively, these safety and immunogenicity data support administration of JN.1 lineage-adapted vaccines for the 2024-2025 season. CLINICALTRIALS: gov Identifier: NCT05997290.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Diya O, Gayed J, Lowry FS, et al. A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults ≥18 years old. Vaccine. 2025. PMID: 39999538. doi:10.1016/j.vaccine.2025.126869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。